Skip to content
DraconiticResearch
Search Sources API
194,226 studies31 sourcesUpdated 53 min ago
Peer-reviewedLicence not statedEuropean Urology Oncology

Adrenal Metastases Are Associated with Poor Outcomes in Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Nivolumab in the GETUG-AFU-26 NIVOREN Phase 2 Trial

  • Emilien Billon
  • Cécile Dalban
  • Stephane Oudard
  • Christine Chevreau
  • Brigitte Laguerre
  • Philippe Barthélémy
  • Delphine Borchiellini
  • Lionnel Geoffrois
  • Sylvie Negrier
  • Florence Joly
  • Antoine Thiery-Vuillemin
  • Marine Gross-Goupil
8 more authors
  • Frederic Rolland
  • Frank Priou
  • Hakim Mahammedi
  • Florence Tantot
  • Bernard Escudier
  • Sylvie Chabaud
  • Laurence Albiges
  • Gwenaelle Gravis
Open at sourceDOICite

Related

  1. Efficacy and safety of nivolumab in bone metastases from renal cell carcinoma: Results of the GETUG-AFU26-NIVOREN multicentre phase II study
    Maud Velev, Cécile Dalban, Christine Chevreau +24
    European Journal of CancerPeer-reviewedLicence not stated17 citedGeneral biologyHAL
  2. Impact of previous nivolumab treatment on the response to taxanes in patients with recurrent/metastatic head and neck squamous cell carcinoma
    Emeline Guiard, Florian Clatot, Caroline Even +5
    European Journal of CancerPeer-reviewedPublisher termsFull text20 citedGeneral biologyOncologyHAL
  3. Real-world comparative outcomes of first-line immune combinations (ICI-ICI vs ICI-TKI) in metastatic renal cell carcinoma with sarcomatoid features.
    Sara Elena Rebuzzi, Fabrizio Di Costanzo, Roberto Filippi +46
    OncoimmunologyPeer-reviewedCC BY-NCFull textImmunologyOncologyEurope PMCPMC
  4. Efficacy and Safety of Concomitant Proton Pump Inhibitor and Nivolumab in Renal Cell Carcinoma: Results of the GETUG-AFU 26 NIVOREN Multicenter Phase II Study
    Elie Rassy, Cécile Dalban, Emeline Colomba +17
    Clinical Genitourinary CancerPeer-reviewedLicence not stated19 citedGeneral biologyHAL
  5. Updated outcomes of AdjuMel study: real-world data in patients with resected stage III-IV melanoma treated with adjuvant nivolumab in France
    S. Dalle, P. Saiag, C. Lebbé +13
    European journal of cancer skin cancerPeer-reviewedCC BY-NC-ND 4.0Full text1 citedImmunologyEpidemiology & public healthHAL

Cite

BibTeXRIS
BibTeX
@article{billon2026adrenal,
  title = {{Adrenal Metastases Are Associated with Poor Outcomes in Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Nivolumab in the GETUG-AFU-26 NIVOREN Phase 2 Trial}},
  author = {Emilien Billon and Cécile Dalban and Stephane Oudard and Christine Chevreau and Brigitte Laguerre and Philippe Barthélémy and Delphine Borchiellini and Lionnel Geoffrois and Sylvie Negrier and Florence Joly and Antoine Thiery-Vuillemin and Marine Gross-Goupil and Frederic Rolland and Frank Priou and Hakim Mahammedi and Florence Tantot and Bernard Escudier and Sylvie Chabaud and Laurence Albiges and Gwenaelle Gravis},
  journal = {European Urology Oncology},
  year = {2026},
  month = sep,
  doi = {10.1016/j.euo.2023.09.009},
  url = {https://hal.science/hal-05744151v1},
}
RIS
TY  - JOUR
TI  - Adrenal Metastases Are Associated with Poor Outcomes in Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Nivolumab in the GETUG-AFU-26 NIVOREN Phase 2 Trial
AU  - Emilien Billon
AU  - Cécile Dalban
AU  - Stephane Oudard
AU  - Christine Chevreau
AU  - Brigitte Laguerre
AU  - Philippe Barthélémy
AU  - Delphine Borchiellini
AU  - Lionnel Geoffrois
AU  - Sylvie Negrier
AU  - Florence Joly
AU  - Antoine Thiery-Vuillemin
AU  - Marine Gross-Goupil
AU  - Frederic Rolland
AU  - Frank Priou
AU  - Hakim Mahammedi
AU  - Florence Tantot
AU  - Bernard Escudier
AU  - Sylvie Chabaud
AU  - Laurence Albiges
AU  - Gwenaelle Gravis
PY  - 2026
DA  - 2026/09/09
JO  - European Urology Oncology
DO  - 10.1016/j.euo.2023.09.009
UR  - https://hal.science/hal-05744151v1
SN  - 2588-9311
ER  -